Benzinga | Oct 27, 2021 07:16AM EDT

EXCLUSIVE: Pasithea Administers First IV Ketamine Infusion Therapy In Depression Patients

* Pasithea Therapeutics Corp's (NASDAQ:KTTA) wholly-owned subsidiary, Pasithea Clinics, has administered intravenous (IV) ketamine therapy to its first patients with treatment-resistant depression.

* Pasithea Clinics commenced IV ketamine infusion therapy in Knightsbridge, London.

* In sub-anesthetic doses, ketamine has shown efficacy and a rapid and sustained effect in some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder.

* Ketamine is an FDA-approved anesthetic and was introduced over 50 years ago. It has recently been repurposed in significantly lower doses to treat psychiatric disorders.

* Pasithea has clinical partnerships to administer its IV ketamine treatment. In the U.K., Pasithea has partnered with ZEN Healthcare -- a network of health clinics in London.

* In the U.S., it has partnered with The IV Doc Inc to provide in-home IV ketamine infusions.

* Related: EXCLUSIVE: Pasithea Therapeutics Launches First Ketamine Clinic In The UK.

* Price Action: KTTA shares closed 1.50% higher at $2.71 on Tuesday.

* Photo by Michaelberry via Wikimedia